C10orf67

Summary

C10orf67 (chromosome 10 open reading frame 67, HGNC:28716) is a protein-coding gene on chromosome 10p12.2, encoding Uncharacterized protein C10orf67, mitochondrial (Q8IYJ2).

Predicted to be located in mitochondrion.

Source: NCBI Gene 256815 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 15 total — 1 pathogenic
• MANE Select transcript: NM_001371909

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28716
Approved symbol	C10orf67
Name	chromosome 10 open reading frame 67
Location	10p12.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC46732, bA215C7.4
Ensembl gene	ENSG00000179133
Ensembl biotype	protein_coding
Entrez	256815

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 nonsense_mediated_decay

ENST00000323327, ENST00000376500, ENST00000376501, ENST00000636213, ENST00000649478, ENST00000673651, ENST00000892141, ENST00000953961

RefSeq mRNA: 4 — MANE Select: NM_001371909 NM_001351306, NM_001365862, NM_001371909, NM_153714

CCDS: CCDS44365, CCDS91221

Canonical transcript exons

ENST00000636213 — 16 exons

Exon	Start	End
ENSE00001092024	23320741	23320815
ENSE00001180847	23333062	23333182
ENSE00001244864	23322394	23322537
ENSE00001470714	23267195	23267254
ENSE00001470715	23282013	23282078
ENSE00001470716	23289900	23289958
ENSE00001470718	23291132	23291279
ENSE00001470719	23303304	23303459
ENSE00001540247	23239729	23239816
ENSE00003794064	23202696	23204255
ENSE00003795072	23223744	23223818
ENSE00003797935	23250455	23250520
ENSE00003798026	23250612	23250691
ENSE00003798943	23266262	23266426
ENSE00003800665	23223598	23223658
ENSE00003893088	23344569	23344797

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 88.64.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0997 / max 5.3029, expressed in 41 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108677	0.0841	32
108675	0.0156	7

Top tissues by expression

227 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	88.64	gold quality
tendon of biceps brachii	UBERON:0008188	88.27	silver quality
right uterine tube	UBERON:0001302	82.14	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	81.27	gold quality
right testis	UBERON:0004534	78.68	gold quality
left testis	UBERON:0004533	78.62	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.11	gold quality
testis	UBERON:0000473	76.85	gold quality
bronchial epithelial cell	CL:0002328	73.99	gold quality
bronchus	UBERON:0002185	73.14	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	71.25	gold quality
nasal cavity mucosa	UBERON:0001826	70.24	gold quality
secondary oocyte	CL:0000655	69.88	silver quality
parotid gland	UBERON:0001831	69.52	gold quality
biceps brachii	UBERON:0001507	69.30	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	68.52	gold quality
gingival epithelium	UBERON:0001949	68.06	gold quality
right lung	UBERON:0002167	68.02	gold quality
gingiva	UBERON:0001828	66.96	gold quality
upper leg skin	UBERON:0004262	65.52	silver quality
pituitary gland	UBERON:0000007	65.44	gold quality
myocardium	UBERON:0002349	65.27	gold quality
adenohypophysis	UBERON:0002196	64.58	gold quality
nasal cavity epithelium	UBERON:0005384	63.93	gold quality
upper lobe of left lung	UBERON:0008952	63.78	gold quality
esophagus squamous epithelium	UBERON:0006920	62.84	gold quality
cartilage tissue	UBERON:0002418	62.68	gold quality
endothelial cell	CL:0000115	62.59	gold quality
fallopian tube	UBERON:0003889	62.19	gold quality
oviduct epithelium	UBERON:0004804	61.95	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.58

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

62 targeting C10orf67, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-573	99.55	67.44	955
HSA-MIR-3616-5P	99.55	67.02	989
HSA-MIR-451B	99.55	68.28	1380

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:dkey-188g12.1	ENSDARG00000076896
mus_musculus	4921504E06Rik	ENSMUSG00000026734
rattus_norvegicus	C17h10orf67	ENSRNOG00000021898

Protein

Protein identifiers

Uncharacterized protein C10orf67, mitochondrial — Q8IYJ2 (reviewed: Q8IYJ2)

All UniProt accessions (6): Q8IYJ2, A0A1B0GUT5, A0A3B3IRX4, A0A6E1W0W4, A0A6E2AE84, Q5SXQ8

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with NOD2.

Subcellular location. Mitochondrion.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IYJ2-1	1	yes
Q8IYJ2-2	2

RefSeq proteins (4): NP_001338235, NP_001352791, NP_001358838, NP_714925 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR031651	DUF4709	Domain
IPR031711	DUF4724	Domain
IPR040119	C10orf67-like	Family

Pfam: PF15821, PF15852

UniProt features (10 total): region of interest 2, coiled-coil region 2, compositionally biased region 2, splice variant 2, transit peptide 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IYJ2-F1	71.37	0.41

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 29 (showing top): RFX1_02, chr10p12, RYTGCNWTGGNR_UNKNOWN, DODD_NASOPHARYNGEAL_CARCINOMA_DN, MIKKELSEN_ES_HCP_WITH_H3_UNMETHYLATED, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED, KOYAMA_SEMA3B_TARGETS_DN, F10_TARGET_GENES, ZBTB12_TARGET_GENES, ZNF2_TARGET_GENES, MIR759, MIR5007_5P, MIR3667_5P, DESCARTES_MAIN_FETAL_CILIATED_EPITHELIAL_CELLS, DESCARTES_FETAL_LUNG_CILIATED_EPITHELIAL_CELLS

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

146 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
C10orf67	ARMC3	Q5W041	441
C10orf67	ANXA11	P50995	400
C10orf67	LURAP1L	Q8IV03	394
C10orf67	PRR16	Q569H4	380
C10orf67	CCDC134	Q9H6E4	370
C10orf67	ENTR1	Q96C92	370
C10orf67	FAM117B	Q6P1L5	351
C10orf67	RAB23	Q9ULC3	311
C10orf67	CCDC88B	A6NC98	307
C10orf67	PPP2R3B	Q9Y5P8	305
C10orf67	LDOC1	O95751	301
C10orf67	ANKHD1	Q8IWZ3	292
C10orf67	BTNL2	Q9UIR0	290
C10orf67	OTUD1	Q5VV17	289
C10orf67	RETSAT	Q6NUM9	285

IntAct

14 interactions, top by confidence:

A	B	Type	Score
NOD2	C10orf67	psi-mi:“MI:0915”(physical association)	0.550
C10orf67	NOD2	psi-mi:“MI:0915”(physical association)	0.550
NOD2	C10orf67	psi-mi:“MI:2364”(proximity)	0.550
BMI1	MEIS3P1	psi-mi:“MI:0914”(association)	0.350
ATF1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ATF3	C11orf98	psi-mi:“MI:0914”(association)	0.350
CASP3	C11orf98	psi-mi:“MI:0914”(association)	0.350
CTNNA1	EFCAB5	psi-mi:“MI:0914”(association)	0.350
FOS	MYO1G	psi-mi:“MI:0914”(association)	0.350
GATA2	EFCAB5	psi-mi:“MI:0914”(association)	0.350
C10orf67		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): C10orf67 (Two-hybrid), NOD2 (FRET), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), C10orf67 (Two-hybrid), TNF (Two-hybrid), RPLP2 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A1W2P884, A2AM05, A2AUM9, A2BGP7, E1U8D0, O94964, P60853, Q05D60, Q0KK56, Q2M243, Q32LC2, Q3UPP8, Q3V036, Q5PQQ9, Q5PQS2, Q5R9L2, Q5SZL2, Q5U3Z6, Q5U465, Q5U4W1, Q5XJA2, Q6AXZ4, Q6AYB8, Q6DIS8, Q6IPM2, Q6NRK1, Q6NRX3, Q6P2H3, Q6P402, Q6PCQ0, Q70YC5, Q7M6Y5, Q86YF9, Q86Z20, Q8BG89, Q8BMD2, Q8BMK0, Q8BVC4, Q8CFC9, Q8CGZ2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

15 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2429343	NM_001371909.1(C10orf67):c.1570+4090T>C	Pathogenic

SpliceAI

718 predictions. Top by Δscore:

Variant	Effect	Δscore
10:23320736:CTCA:C	donor_loss	1.0000
10:23320737:TCA:T	donor_loss	1.0000
10:23320738:CA:C	donor_loss	1.0000
10:23320739:A:AC	donor_gain	1.0000
10:23320739:ACCT:A	donor_loss	1.0000
10:23320740:C:CA	donor_loss	1.0000
10:23320740:C:CC	donor_gain	1.0000
10:23320811:TCATT:T	acceptor_gain	1.0000
10:23320812:CATT:C	acceptor_gain	1.0000
10:23320812:CATTC:C	acceptor_gain	1.0000
10:23320813:ATT:A	acceptor_gain	1.0000
10:23320813:ATTC:A	acceptor_loss	1.0000
10:23320814:TT:T	acceptor_gain	1.0000
10:23320815:TCT:T	acceptor_loss	1.0000
10:23320816:C:CC	acceptor_gain	1.0000
10:23320816:C:T	acceptor_loss	1.0000
10:23320817:T:A	acceptor_loss	1.0000
10:23320823:C:CT	acceptor_gain	1.0000
10:23320824:A:T	acceptor_gain	1.0000
10:23322389:TTTAC:T	donor_loss	1.0000
10:23322390:TTACC:T	donor_loss	1.0000
10:23322391:TAC:T	donor_loss	1.0000
10:23322392:A:AC	donor_gain	1.0000
10:23322392:A:T	donor_loss	1.0000
10:23322393:C:A	donor_loss	1.0000
10:23322393:C:CC	donor_gain	1.0000
10:23322534:TCAT:T	acceptor_gain	1.0000
10:23322535:CAT:C	acceptor_gain	1.0000
10:23322535:CATC:C	acceptor_gain	1.0000
10:23322538:C:CC	acceptor_gain	1.0000

AlphaMissense

3681 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:23320770:C:G	A174P	0.999
10:23239784:C:A	R461M	0.998
10:23239769:C:G	R466P	0.997
10:23239783:C:A	R461S	0.997
10:23239783:C:G	R461S	0.997
10:23239784:C:G	R461T	0.997
10:23239789:A:C	F459L	0.997
10:23239789:A:T	F459L	0.997
10:23239791:A:G	F459L	0.997
10:23239796:T:A	E457V	0.997
10:23239801:C:A	K455N	0.997
10:23239801:C:G	K455N	0.997
10:23239805:A:G	L454P	0.997
10:23250464:A:G	L447P	0.996
10:23239792:C:A	M458I	0.995
10:23239792:C:G	M458I	0.995
10:23239792:C:T	M458I	0.995
10:23320798:T:A	R164S	0.995
10:23320798:T:G	R164S	0.995
10:23239805:A:T	L454H	0.994
10:23289929:C:G	A295P	0.994
10:23289949:A:G	L288P	0.994
10:23239785:T:C	R461G	0.993
10:23282077:A:G	L305S	0.993
10:23320764:C:G	A176P	0.993
10:23320778:A:G	L171S	0.993
10:23239796:T:C	E457G	0.992
10:23320784:T:G	Q169P	0.992
10:23333139:C:G	D85H	0.992
10:23239775:A:G	L464P	0.991

dbSNP variants (sampled 300 via entrez): RS1000002483 (10:23266310 G>A,T), RS1000018063 (10:23226783 A>G,T), RS1000020202 (10:23293837 G>A,C), RS1000026871 (10:23266717 G>C,T), RS1000035128 (10:23266734 G>A), RS1000052062 (10:23212379 A>G), RS1000063468 (10:23236848 G>C), RS1000080287 (10:23267011 C>T), RS1000089731 (10:23291539 A>T), RS1000155359 (10:23299843 T>C), RS1000164773 (10:23324093 C>T), RS1000216935 (10:23341474 T>A,C), RS1000217573 (10:23214273 A>G), RS1000220582 (10:23247287 A>G), RS1000230238 (10:23272463 T>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:615935, MIM:616720, MIM:125853

GenCC curated gene-disease

Mondo (3): pancreatic agenesis 2 (MONDO:0014406), congenital myasthenic syndrome 19 (MONDO:0014745), type 2 diabetes mellitus (MONDO:0005148)

Orphanet (2): Partial pancreatic agenesis (Orphanet:2805), Congenital myasthenic syndrome (Orphanet:590)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000212_1	Crohn’s disease and sarcoidosis (combined)	4.000000e-06
GCST004867_31	Systemic lupus erythematosus	7.000000e-06
GCST006979_564	Heel bone mineral density	4.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D003924	Diabetes Mellitus, Type 2	C18.452.394.750.149; C19.246.300

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, increases expression	2
propionaldehyde	increases expression	1
nickel sulfate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
Sunitinib	decreases expression	1
Arsenic	affects expression	1
Benzo(a)pyrene	affects methylation	1
Lipopolysaccharides	decreases reaction, increases expression	1
Smoke	increases abundance, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Propofol	increases expression	1
Aflatoxin B1	increases methylation	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00006163	PHASE4	COMPLETED	Computer-assisted Diabetes Self-management Interventions
NCT00036504	PHASE4	COMPLETED	Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin
NCT00044460	PHASE4	COMPLETED	Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00095446	PHASE4	COMPLETED	NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
NCT00101751	PHASE4	COMPLETED	INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
NCT00110370	PHASE4	COMPLETED	Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
NCT00110448	PHASE4	COMPLETED	Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
NCT00118950	PHASE4	COMPLETED	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118963	PHASE4	COMPLETED	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
NCT00121966	PHASE4	COMPLETED	South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
NCT00123604	PHASE4	COMPLETED	Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
NCT00123643	PHASE4	COMPLETED	Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
NCT00124397	PHASE4	COMPLETED	Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00129233	PHASE4	COMPLETED	Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
NCT00133718	PHASE4	COMPLETED	A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
NCT00135070	PHASE4	TERMINATED	Hospital In-Patient Insulin Study
NCT00141232	PHASE4	COMPLETED	Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00144144	PHASE4	UNKNOWN	A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
NCT00149331	PHASE4	COMPLETED	The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy
NCT00162357	PHASE4	COMPLETED	Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00174681	PHASE4	COMPLETED	Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
NCT00174824	PHASE4	COMPLETED	Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
NCT00177398	PHASE4	COMPLETED	Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
NCT00179400	PHASE4	COMPLETED	The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
NCT00184561	PHASE4	COMPLETED	Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
NCT00184626	PHASE4	COMPLETED	Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
NCT00191178	PHASE4	COMPLETED	Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
NCT00191282	PHASE4	COMPLETED	Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00191464	PHASE4	COMPLETED	Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00192803	PHASE4	UNKNOWN	Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
NCT00202033	PHASE4	COMPLETED	Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes
NCT00205660	PHASE4	COMPLETED	Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00212290	PHASE4	COMPLETED	Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212303	PHASE4	COMPLETED	Exercise Training in Type 2 Diabetes and Hypertension
NCT00225342	PHASE4	WITHDRAWN	Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
NCT00238472	PHASE4	COMPLETED	A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
NCT00239538	PHASE4	COMPLETED	SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
NCT00240253	PHASE4	COMPLETED	A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
NCT00240422	PHASE4	COMPLETED	Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
NCT00241085	PHASE4	COMPLETED	Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus